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Does community-based point
of care HIV testing reduce late
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Nick Cooper3 and Michael Brady4
Abstract
The objective of this study was to investigate if patients diagnosed in community clinics have higher baseline CD4 cell
counts than those diagnosed in Genitourinary medicine (GUM)/HIV clinics. We undertook a retrospective review of
baseline CD4 cell counts for patients receiving a reactive HIV test in community-testing clinics. Eleven local HIV clinics
were contacted to determine the baseline CD4 cell counts of these patients. Baseline CD4 cell counts of those
diagnosed in the community were compared with mean local GUM/HIV clinic and median national baseline CD4 cell
count for their year of diagnosis. Clients diagnosed in community settings had a mean baseline CD4 cell count of
481 cells/mm3 (SD 236 cells/mm3) and median baseline of 483 cells/mm3 (interquartile range 311–657 cells/mm3). This
was significantly higher than those diagnosed in the GUM/HIV clinic local to the community-testing site (mean baseline
CD4 397 cells/mm3, p¼ 0.014) and the national median for that year (336 cells/mm3, p< 0.001). HIV testing in com-
munity settings identifies patients at an earlier stage of infection than testing in clinical settings.
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Introduction
Late diagnosis of HIV is an important predictor of
morbidity, short-term mortality and HIV transmis-
sion.1 In 2014, two ﬁfths of HIV diagnoses in the UK
were made ‘late’ (with a CD4 cell count <350 cells/mm3
within three months of diagnosis).2
Most HIV tests in the UK are undertaken in clinical
settings. These include primary care and antenatal
clinics. Community HIV testing facilities are deﬁned:
as those that are based outside pre-existing traditional
healthcare settings. These include both stand-alone
HIV testing services, provided separately from other
clinical services, and venues primarily used for other
purposes (such as social venues or community centres)
where HIV testing is available as an additional service.3
Between 2006 and 2009 in the UK, by far the major-
ity, 73%, of all HIV diagnoses were made in sexual
health clinics and less than 1% in non-clinical settings
including prisons and the Blood Transfusion Service.4
However, people cite overcrowding, waiting times
and the lack of anonymity as disincentives for attending
sexual health clinics for HIV testing.5 Black Africans in
London cited further uncertainty about where to test
and lack of time as barriers to testing.6 While one UK
study looking at the views of men who have sex with
men (MSM) on STI testing in community settings
found that the majority would prefer to test for HIV
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in ‘National Health Service (NHS) specialist service’
settings,7 studies around the world show that HIV test-
ing outside of clinical facilities is acceptable and that
mobile community HIV testing can be cost eﬀective in
diagnosing new cases and eﬀective at enrolling HIV-
positive patients in care before they become ill.8–13
A systematic review of 44 community HIV testing
programmes in resource-rich countries found that
‘community HIV testing strategies provide an accept-
able alternative to HIV testing in healthcare settings
and are feasible to implement’.3
Many of these studies were, however, undertaken in
either developing world settings or the United States.
Neither of these environments accurately reﬂects the
state-funded and free-at-the-point-of-use healthcare
system found in the UK. A US study found that clients
testing in the community were older and more likely to
be HIV-positive than those testing in clinical settings,14
while a small UK study15 and most developing world
studies found the reverse.
Terrence Higgins Trust (THT) is the largest HIV
and Sexual Health charity in the UK and has run
community HIV testing programmes since 2004.
THT community HIV testing clinics have performed
more than 14,000 HIV tests since 2008 in England
and Wales. These nurse-led or Healthcare Assistant-
delivered clinics are located in easily accessible sites
including high street oﬃces, saunas, libraries and
churches and often operate on evenings and week-
ends. A small study evaluating one such service
found that the average baseline CD4 cell count was
higher, although not signiﬁcantly so, when compared
to clients of the local Genitourinary medicine
(GUM)/HIV clinic.15 For the period 2008–2012 we
used data from THT’s community HIV testing clinics
to determine whether people receiving a reactive HIV
test at a community-testing site were identiﬁed at a
diﬀerent stage of HIV infection compared with those
diagnosed in clinical settings and national averages.
We refer to these clinical settings as GUM/HIV
clinics due to the integrated nature of many UK
sexual health services. Patients may present for HIV
testing at a primary healthcare or GUM clinic but
baseline CD4 data are recorded and provided by a
hospital HIV clinic. We deﬁned a patient’s ﬁrst rec-
orded CD4 cell count as their baseline CD4 cell
count.
Objectives
1. To determine if newly diagnosed patients receiving a
reactive point-of-care HIV test in a community set-
ting have diﬀerent baseline CD4 cell count when com-
pared with patients diagnosed in clinical settings.
2. To explore the care pathway of people testing
for HIV in community clinics, including what pro-
portion of patients engages with subsequent
clinical care.
Methods
We received ethical approval from South East Coast
– Kent NRES Committee as project 12/LO/1778.
Following this, we searched THT’s database and
paper records to identify people who had received a
reactive HIV test in a community clinic between 2008
and 2012. We contacted the hospital speciﬁed on
each patient’s care pathway to determine if they
had accessed subsequent HIV care and, if so, to
establish their baseline CD4 cell count. We provided
an encrypted list of the patients’ Soundex (scrambled
surname and date of birth code) to Public Health
England (PHE) to ascertain whether patients had
sought HIV care elsewhere in England or Wales
and, if so, what had been their baseline CD4 cell
count. PHE were also able to identify whether
patients had received a CD4 cell count pre-dating
their visit to THT’s community clinic.
Study population
Figure 1 shows the ﬂow chart of how we arrived at our
ﬁnal sample of 74 patients who were newly diagnosed
with HIV in a community clinic and had a known base-
line CD4 cell count.
A demographic breakdown of the sample is given in
Table 1.
Statistical methods
Comparator CD4 cell counts were obtained from the
hospital HIV clinics where THT community-testing
patients went for conﬁrmatory tests and care. These
clinics provided annual mean averages of their
patients’ baseline CD4 cell counts from 2008 to 2012.
PHE provided national median CD4 cell counts
from 2008 to 2011. The national median CD4 cell
count for 2012 was not available at the time of
data analysis. These, however, showed consistency
between years, and clients who were tested in 2012
were assigned the PHE value from 2011. Medians are
used instead of means here because extreme outliers
are found at the national level and these skew the
mean values. There were no signiﬁcant outliers in
the THT data we collected and so we compared
means for this part of the study.
T-tests were performed to compare the mean base-
line CD4 cell count of the community-testing clients
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who presented for hospital HIV care to the mean
baseline CD4 cell count for the HIV service to which
they were referred, in the year they presented. PHE
provided national median baseline CD4 cell counts.
We performed Wilcoxon signed rank tests to compare
community-tested clients to the national median from
PHE for the year they were tested.
To control for confounders, we performed further
tests where individuals were categorised by gender,
sexuality and ethnicity and compared with clinic and
national level medians for the same demographics. Due
to very small sample sizes in the demographic-speciﬁc
tests, we pooled these into a meta-analysis to estimate
an overall eﬀect.
We performed further t-tests to ascertain if commu-
nity-testing clients were more likely to be diagnosed at a
CD4 cell count >350 or >500 cells/mm3 compared to
those testing in clinical settings. These ﬁgures were
chosen as they were the recommended CD4 cell
counts at which patients were advised to start treatment
in the UK and the US, respectively, at the time of test-
ing. Finally, we performed a binary logistic analysis to
examine which demographic factors predicted whether
an individual presented for a follow-up appointment.
Results
Two-hundred and fourteen people received a reactive
HIV diagnosis in the study period (2.0%). Seventy-four
(36%) ﬁt the inclusion criteria of being newly diagnosed
and subsequently conﬁrmed as accessing HIV treat-
ment in England or Wales. Thirty-six patients were
already aware they were HIV-positive at the time of
their community clinic test and 104 patients could not
be linked to a subsequent baseline CD4 cell count. The
mean baseline CD4 cell count of patients who tested
positive in a THT community clinic was 84 cells/mm3
higher than that of patients diagnosed at the referral
hospitals’ GUM/HIV clinics (p¼ 0.014) (see Table 1).
Wilcoxon signed rank tests showed that community-
tested patients were signiﬁcantly more likely to have
higher CD4 cell count than the national population.
Fifty-nine community-tested patients had CD4 cell
counts higher than the national median while 20 pre-
sented below. Clients diagnosed in community clinics
were signiﬁcantly more likely to be diagnosed at a
baseline CD4 >350 cells/mm3 than clients diagnosed
in clinical settings. This eﬀect was not replicated for
baseline CD4 cell count >500 cells/mm3.
T-tests controlling for sexuality, ethnicity and gender
found that MSM, diagnosed in community settings,
had signiﬁcantly higher baseline CD4 cell counts than
clients tested in clinical settings and were signiﬁcantly
more likely to be diagnosed at a baseline CD4
>350 cells/mm3 (Figure 2).
Table 2 shows the results of a binary logistic
regression analysis testing the demographic predictors
of follow-up likelihood. The most important demo-
graphic predictor is being homosexual or bisexual
(these categories were pooled in order to compare
this group to heterosexual participants). MSM were
almost four times more likely to present for follow-up
after a reactive test in a community clinic. Being male
and white was also associated with higher odds of
Figure 1. Flow chart of how we arrived at our final sample of 74 patients who were newly diagnosed with HIV in a community clinic
and had a known baseline CD4 cell count.
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presenting for follow-up although these results are
not statistically signiﬁcant. Age was not a predictor
of likely follow-up.
Previously diagnosed patients and re-engagement
Thirty-six people were already aware that they were
HIV-positive when they took an HIV test at a commu-
nity clinic. Of these, six patients were conﬁrmed as sub-
sequently accessing specialist HIV services having
never, or not within the last two years, received HIV
care in the UK. They sought care a median of two days
(IQR 1.5–3) following their community HIV test.
Sixteen patients informed the nurse at the community
clinic that they were aware of their positive HIV status.
Notes in the patients’ records showed that nurses coun-
selled previously diagnosed patients about the import-
ance of accessing HIV treatment and gave advice on
how to access care. Twenty patients had a pre-existing
baseline CD4 cell count, which was taken at a median
Table 1. Demographics of patients testing in HIV community clinics, those who received a reactive test, those who had received an
HIV diagnosis prior to their community clinic test and those who were newly diagnosed in the community clinic and could be traced to
a baseline CD4 cell count.
Total patients
tested in
community clinics
(n¼ 10,560) (%)
Total reactive
population in
community clinics
(n¼ 214) (%)
Patients with
new HIV
diagnoses in
community clinics
(n¼ 36) (%)
Newly diagnosed
patients with
CD4 cell count
originally tested
in community
clinics (n¼ 74) (%)
Ethnicity
White UK 5102 (48) 89 (42) 6 (17) 49 (66)
White non-UK 562 (5) 16 (7) 2 (6) 9 (12)
Black African 2721 (26) 80 (37) 23 (64) 12 (16)
Other Black
including mixed
957 (9) 11 (5) 2 (6) 3 (4)
Asian and mixed 795 (8) 7 (3) 1 (3) 1 (4)
Ethnicity unknown 426(4) 11 (5) 2 (6) 0 (0)
Sexuality
Heterosexual 6840 (65) 96 (45) 26 (72) 16 (22)
Homosexual 2039 (19) 82 (38) 4 (11) 51 (69)
Bisexual 477 (5) 13 (13) 3 (8) 5 (7)
Sexuality unknown 1207 (11) 23 (23) 3 (8) 2 (3)
Gender
Female 3059 (29) 66 (31) 19 (53) 10 (14)
Male 7504 (71) 148 (69) 17 (47) 64 (86)
Median age 29 32 36 35
Mean baseline CD4 cell count for patients diagnosed
in community setting (cells/mm3)
481 (SD 236) (versus mean baseline CD4 cell
count for patients diagnosed in referral
hospital p¼ 0.014)
Mean baseline CD4 cell count for patients diagnosed in referral hospital 397 (SD 34)
Median baseline CD4 cell count for patients diagnosed
in a community setting (IQR)
483 (311–657) (versus Public Health England’s
national median baseline CD4 cell
count p< 0.001)
Public Health England’s national median baseline CD4 cell count (IQR not
available)
336
Median number of days between reactive community test and presenting to a
hospital HIV clinic for a CD4 test in newly diagnosed patients (IQR)
3 (1–9)
Median number of days between reactive community test and presenting to a
hospital HIV clinic for a CD4 test in patients with identified pre-existing HIV
diagnosis (IQR)
2 (1.5–3)
HIV: human immunodeficiency virus; IQR: interquartile range; SD: standard deviation.
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of 1010 days (IQR 431–1859) before their community
clinic HIV test.
Discussion
Our results show that patients receiving an HIV diag-
nosis through community-testing are, on average, diag-
nosed at an earlier stage of infection when compared
with patients testing in clinical settings. They are also
signiﬁcantly more likely to be diagnosed at a baseline
CD4 above 350 cells/mm3. These associations are sig-
niﬁcant for the aggregated patient group and for MSM
patients. It is not signiﬁcant for Black African or
heterosexual clients, but the average CD4 cell count
at baseline was still higher when tested in community
settings, compared with clinical settings. In our study,
only a small number of Black African and heterosexual
clients could be linked to a baseline CD4 cell count, and
the small sample size is likely to contribute to this
lack of statistical signiﬁcance. Those that presented to
a hospital for conﬁrmatory testing and care presented a
median of three days after their community HIV test.
This falls within BHIVA’s 2013 Standard of Care
guidelines that indicate that all patients should be
oﬀered a full baseline assessment, including a CD4
cell count test, within two weeks of diagnosis with
HIV.16 It is possible that people diagnosed in commu-
nity settings are more likely to access care sooner after
diagnosis than those in clinical settings and will there-
fore appear to have a higher baseline CD4 cell count.
A 2014 study found that adults who received their HIV
diagnosis in primary care or a community setting were
signiﬁcantly less likely to have presented for HIV care
within one month, compared to those who were diag-
nosed in an integrated GUM/HIV clinic 76% versus
91%, p< 0.001).17
Access to care
One hundred and four (49%) clients could not be con-
ﬁrmed as having accessed HIV care, therefore we were
unable to link them to a baseline CD4 cell count.
This could reﬂect some patients using false names or
dates of birth when testing in community clinics in add-
ition to those patients who have yet to seek HIV care.
It may also represent some clients with false-reactive
HIV point-of-care tests that were not subsequently con-
ﬁrmed as HIV-positive and therefore did not have a
baseline CD4 cell count. Binary logistic regression ana-
lysis found that being male and white increased the
likelihood of being linked to follow-up; however,
these results are not statistically signiﬁcant, and there
was no eﬀect of age. MSM clients were almost four
Demographic
MSM
Heterosexual men
Heterosexual women
Black African heterosexual women
Overall (I-squared = 0.0%, p= 0.0938)
NOTE: Weights are from random effects analysis
–477 4770
Black African heterosexual men
Differences in
Medians (95% Cl)
%
Weight
99.00 (61.11, 155.52)
24.00 (–230.70, 335.33)
104.00 (–151.40, 162.97)
57.00 (–225.40, 476.90)
34.50 (–191.40, 149.90)
92.95 (50.08, 135.83)
82.46
2.29
7.44
1.49
6.31
100.00
Figure 2. A forest plot showing the difference in the mean baseline CD4 cell count between those tested in a THT community clinic
and the national median for each demographic group. CD4 cell count is given on the X-axis (cells/mm3).
Table 2. Results from binary logistic regression analysis of
follow-up. Odds ratios, significance tests and 95% confidence
intervals are presented for demographic indicators of the odds of
presenting at follow-up after THT community testing. An odds
ratio of higher than one denotes higher odds of follow-up.
Follow-up
Odds
ratio P-value 95% CI
Male (ref female) 1.73 0.285 0.63 4.73
MSM (ref heterosexual) 3.84 0.015 1.29 11.40
White (ref. non-white) 1.97 0.208 0.69 5.65
Age at test 1.00 0.823 0.97 1.04
CI: confidence interval.
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times more likely to be linked to follow-up care com-
pared with heterosexual clients. Most of the heterosex-
ual men who had reactive tests identiﬁed themselves as
of African descent although we are unable to ascertain
when they had migrated to the UK.
Diﬃculty in maintaining referral pathways is an
established challenge in community testing.18 This is
possibly because while community testing removes bar-
riers to HIV testing, these barriers remain in place when
it is necessary for the patient to access hospital-based
HIV care. Community testing may allow clients to test
earlier than they otherwise would have done, but this
does not mean they will be ready to accept their HIV
diagnosis any sooner. The barriers a person needs to
overcome to access clinic-based testing may mean they
are more motivated to test and will be more prepared to
proceed to seeking care.
In previous studies on community HIV testing, a
similar proportion of reactive patients were conﬁrmed
to have accessed HIV care.19 Studies in the United
States found that 48% of the patients who received a
reactive HIV test result in South Carolina and 77% in
New York City linked to care within three months of
their test.20,21 A systematic review on HIV testing in
community setting found only three studies collected
data on the proportion of HIV diagnosed patients
who transferred to care, and that these rates were 75–
100% of all diagnosed patients.3 All three studies were
based in saunas and provided community HIV testing
to MSM only.15,22,23
Other studies have demonstrated that access to and
retention in HIV care varies between demographic
groups. A South London HIV clinic investigated the
loss to follow-up among its patients. It found that while
more than a quarter of the heterosexual male black
African (26.2%) and Caribbean (29.3%) patients were
lost to all UK HIV care and follow-up, this occurred
with less than 18% of white and black MSM and white
heterosexual male and female patients.24
A study of Black Africans in the UK found that ‘fear
of stigmatisation, deportation and expectations of HIV
as incurable or as a ‘‘death sentence’’ continue to deter
respondents from taking an HIV test’6. Black African
workshop participants requested that community HIV
testing staﬀ should have training on, ‘1) dealing with
questions about immigration status and entitlement to
HIV treatment; [and] 2) discussing prevention of
mother-to-child-transmission . . .’.25 These examples
suggest that HIV-positive black African patients may
have diﬀerent needs and health-seeking behaviours
than MSM patients, despite often being combined
into the same discussion on the utility and outcomes
of community HIV-testing programmes.
THT has a long history of working with gay men and
is well accepted within the UK MSM community. It is
possible that THT’s community clinics are well designed
for the MSM community but need to better understand
the needs of the Black African community to increase
progression from HIV testing into treatment.
Pre-diagnosed patients
Thirty-six patients were aware of their positive HIV
status before their reactive community clinic test.
Nearly 41% of these patients told the THT staﬀ of
their positive HIV status. Community testing can be
used to identify undiagnosed patients and to provide
a supportive opportunity to re-engage patients with
specialist HIV care.
This study’s ﬁndings were consistent across all ﬁve
years, all demographic groups and all referral clinics.
Participants came from a range of urban and peri-
urban settings in England and Wales. It is therefore
likely that these ﬁndings are generalisable to other
developed world settings with free-at-point-of-use
healthcare systems. Further research is needed to
understand how to improve the number of conﬁrmed
patients seeking care following a reactive HIV test in a
community clinic. This is particularly necessary for
Black African patients. In recent years, THT’s commu-
nity clinics have strengthened their referral pathways
into local HIV services and now ensure that all patients
with a reactive result are followed up at two weeks to
ensure access to care. It would be useful to understand
how community clinics are used to provide entry or re-
engagement points into the medical system, as well as in
counselling existing patients, normalising HIV testing
and providing health promotion opportunities for
HIV-negative patients.
Strengths and limitations
The number of patients who had a reactive HIV test in
the community, had never previously been diagnosed
with HIV and for whom we were able to establish
a baseline CD4 cell count is a small proportion of
the total number of reactive community HIV tests.
The impact of the missing data on the validity of the
study ﬁndings makes it diﬃcult to conclusively state
that increasing the availability of community testing
would increase the national average baseline CD4 cell
count at diagnosis.
This study was dependent on patients providing the
community-testing site with the same information they
used if they sought HIV care. If they provided diﬀerent
information we were unable to link their baseline CD4
cell count. Patients who provided inconsistent informa-
tion between HIV services may diﬀer from those who
provided consistent information. Hospitals listed on the
local THT care pathway are geographically near to
6 International Journal of STD & AIDS 0(0)
the community clinic. Patients more fearful of stigma
may have been more likely to seek HIV care away from
their local area and not attend the referral hospital. We
ameliorated this limitation by collaborating with PHE
to obtain baseline CD4 cell counts from HIV clinics
across the UK. Due to incomplete and delayed report-
ing, PHE did not have all the clinic baseline CD4 cell
counts that we had obtained. There may be other
patients receiving HIV care but are missing from
PHE’s national baseline CD4 database. This would be
a source of bias as it excludes some of the clients who
sought HIV care away from their local area. We did not
have national data for 2012 and used national data
from 2011 as a proxy as we did not expect there to be
much change in the median national baseline CD4 cell
count between 2011 and 2012.
This study does not investigate why patients appear
to be testing at community clinics at an earlier stage of
HIV infection than those testing in clinical settings. It
may be that patients prefer the same-day test results
oﬀered in community clinics, compared to having to
wait for results when testing in a primary or hospital-
based setting. It may be that community clinics avoid
having to provide the documentation that is required to
register with a GP or that could be linked to other
personal records. A minority of patients testing in clin-
ical settings are being tested in accident and emergency
or as part of a medical admission. Their hospital
attendance may be because they are symptomatic with
an HIV-related condition and these patients may never
have tested for HIV until the point at which they
became unwell. We suggest that all of these could be
areas for further research.
Nevertheless, this study is the ﬁrst to test whether
HIV-positive community-tested patients are diagnosed
at a higher baseline CD4 cell count than those who are
tested in clinical settings. Although this study needs to
be replicated with more data, our results suggest that
this is indeed the case.
Conclusion
Our ﬁndings suggest that increasing the scale of com-
munity-based HIV testing would serve the varying
health needs of certain populations at high risk of
HIV and contribute to reducing the proportion of
late HIV diagnoses in the UK. In every category,
we found that community-tested patients had higher
CD4 cell counts than those who ﬁrst tested in a hos-
pital. Early diagnosis is crucial for the greatest bene-
ﬁts of treatment to be achieved. It is futile, however,
to give someone an HIV diagnosis without providing
them with the support they need to access treatment
and this should be central to all community-testing
programmes.
Key messages
. Community HIV testing identiﬁes patients at a sig-
niﬁcantly higher CD4 count than testing in conven-
tional settings.
. Community HIV testing provides useful services to
those already diagnosed with HIV who may not be
accessing care.
. Clients diagnosed with HIV in a community setting
need culturally appropriate support to ensure they
access HIV care.
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